Search research articles
Contact Us
Filters
Showing results (61-70 of 75) with videos related to
Page
of 8
Sort By:
The Journal of Dermatological Treatment
|
February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study
Claudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
Dermatology and Therapy
|
July 24, 2025
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis)
Mariateresa Rossi, Stefano Bighetti, Alessandra Narcisi, et al.
Dermatology and Therapy
|
January 11, 2021
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Paolo Gisondi, Marina Talamonti, Andrea Chiricozzi, et al.
Frontiers in Medicine
|
August 24, 2023
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, et al.
Dermatology and Therapy
|
May 29, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)
Luca Potestio, Cataldo Patruno, Silvia Mariel Ferrucci, et al.
Dermatology and Therapy
|
April 23, 2025
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)
Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Clinical Drug Investigation
|
May 15, 2025
Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis)
Maria Esposito, Paolo Gisondi, Chiara Assorgi, et al.
The Journal of Dermatological Treatment
|
May 7, 2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Clinical, Cosmetic and Investigational Dermatology
|
December 18, 2023
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study
Filomena Russo, Marco Galluzzo, Luca Stingeni, et al.
Dermatology Practical & Conceptual
|
February 28, 2024
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 75) with videos related to
Sort By:
Page
of 8
The Journal of Dermatological Treatment
|
February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study
Claudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
Dermatology and Therapy
|
July 24, 2025
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis)
Mariateresa Rossi, Stefano Bighetti, Alessandra Narcisi, et al.
Dermatology and Therapy
|
January 11, 2021
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Paolo Gisondi, Marina Talamonti, Andrea Chiricozzi, et al.
Frontiers in Medicine
|
August 24, 2023
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, et al.
Dermatology and Therapy
|
May 29, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)
Luca Potestio, Cataldo Patruno, Silvia Mariel Ferrucci, et al.
Dermatology and Therapy
|
April 23, 2025
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)
Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Clinical Drug Investigation
|
May 15, 2025
Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis)
Maria Esposito, Paolo Gisondi, Chiara Assorgi, et al.
The Journal of Dermatological Treatment
|
May 7, 2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Clinical, Cosmetic and Investigational Dermatology
|
December 18, 2023
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study
Filomena Russo, Marco Galluzzo, Luca Stingeni, et al.
Dermatology Practical & Conceptual
|
February 28, 2024
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Page
of 8